Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Diabetes
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Diabetes
    Darbepoetin Alfa Risks Outweigh Benefits for Patients With CKD, Diabetes, and Anaemia: Presented at Renal Week 2009 - (DGDispatch)
    Fenofibrate May Protect Diabetics Against Loss of Renal Function: Presented at Renal Week 2009 - (DGDispatch)
    A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease - (N Engl J Med)
    TopAbstracts in Diabetes 11/03/2009 - (DGNews)
    Paricalcitol Added to Hypertension Therapy Lowers Albuminuria in Patients With Diabetes and Chronic Kidney Disease: Presented at Renal Week 2009 - (DGDispatch)

    News archive

     Recent webcasts/CME - Diabetes
    • Optimizing Insulin-Dependent Diabetes Management in Long-Term Care
    • Insulin-Dependent Diabetes in Long-Term Care: Scope of the Problem and Effective Management
    • Cases in Practice: Incretin-Based Therapies for Common Patient Encounters
      Diabetes Management - Pearls of Lipid Control
      Obesity Management in Patients with Type 2 Diabetes

      Webcasts/CME archive

       Recent cases - Diabetes
        Acquired Perforating Dermatosis: Association with Diabetes and Renal Failure
        A Patient Presenting with Symptomatic Hypomagnesemia Caused by Metformin-Induced Diarrhoea: A Case Report
        Absence of Diabetic Retinopathy in a Patient who has had Diabetes Mellitus for 69 Years, and Inadequate Glycemic Control: Case Report
        Gallbladder Edema in Type 1 Diabetic Patient due to Delayed-type Insulin Allergy
        Compound Heterozygous Mutation of Aquaporin 2 Gene in Woman Patient with Congenital Nephrogenic Diabetes Insipidus

        Cases archive
          




        my personal edition > diabetes > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Type 1 Diabetics May Gain Disease Control Through Transdermal Insulin Patch: Presented at IDF

        By Ed Susman

        PARIS, FRANCE -- Aug. 27, 2003 -- An investigative insulin patch, held in place with bands, appears to help patients achieve diabetes control, researchers reported Tuesday in a poster presentation here at the 18th International Diabetes Foundation Congress.

        "Our findings suggest that the transfer of monomeric insulin molecules through the intact human skin for potential therapeutic use is possible," said Ines Baotic, MD, physician/scientist, Vuk Vrhovac Institute, University Clinic for Diabetes, Endocrinology and Metabolic Diseases, University of Zagreb, Croatia.

        Dr. Baotic and colleagues recruited 43 patients with Type 1 diabetes for the study, which was undertaken with the support of TransDermics Ltd., Ashdod, Israel.

        "The transdermal route of insulin delivery has been a very challenging option due to its lack of proteolytic enzymes," said Dr. Baotic. Although successful in animal models, use of the transdermal route in humans has been frustrated by the size of the insulin molecule. The new formulation of genetically engineered human monocomponent insulin with a microemulsion vehicle, however, appears to work in getting through the human skin.

        In this crossover study, patients wore the patch for eight hours. The testing took place in a hospital setting so the patients could be carefully monitored over three days. Blood glucose monitoring was performed in 15-minute intervals. If blood glucose levels exceeded 5.5 mM/L at 2-, 4- and 6-hour checkpoints, subcutaneous insulin supplements were allowed in individually determined doses.

        Dr. Baotic noted that 22 patients on a patch containing 840 IU of insulin required an average of 1.82 IU of injected insulin to maintain metabolic control compared with 2.17 IU of injected insulin for the 21 patients on a placebo patch (P<0.05).

        On the other hand, a patch saturated with 187.5 IU of insulin did not allow sufficient insulin to pass through the skin to significantly decrease the need for injected drugs.

        Dr. Baotic stated that the 840 IU patch achieved effectiveness in lowering the need for injected insulin about two hours after being placed on the inner side of one upper arm. The patch then controlled diabetes for as long as it was left in place.

        "There were no unexpected adverse events," Dr. Baotic said. "The patch appears safe and well-tolerated." She added, however, that more work needs to be accomplished before the transdermal insulin patch can be individualized for patient use.


        [Study title: Transdermal insulin delivery system for potential therapeutic use to Type 1 diabetics. Abstract 2220]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send